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Biochemical characterization of the initial steps of the Kennedy pathway in
Trypanosoma brucei: the ethanolamine and choline kinases
Federica GIBELLINI*, William N. HUNTER* and Terry K. SMITH†1
*Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, U.K., and †Centre for Biomolecular Sciences, St
Andrews University, North Haugh, St Andrews KY16 9ST, Scotland, U.K.
Ethanolamine and choline are major components of the trypano-
some membrane phospholipids, in the form of GPEtn (glycero-
phosphoethanolamine) and GPCho (glycerophosphocholine).
Ethanolamine is also found as an integral component of the
GPI (glycosylphosphatidylinositol) anchor that is required for
membrane attachment of cell-surface proteins, most notably
the variant-surface glycoproteins. The de novo synthesis of
GPEtn and GPCho starts with the generation of phosphoethanol-
amine and phosphocholine by ethanolamine and choline kinases
via the Kennedy pathway. Database mining revealed two putative
C/EKs (choline/ethanolamine kinases) in the Trypanosoma brucei
genome, which were cloned, overexpressed, purified and charac-
terized. TbEK1 (T. brucei ethanolamine kinase 1) was shown to be
catalytically active as an ethanolamine-specific kinase, i.e. it had
no choline kinase activity. The Km values for ethanolamine and
ATP were found to be 18.4 +− 0.9 and 219 +− 29 μM respectively.
TbC/EK2 (T. brucei choline/ethanolamine kinase 2), on the other
hand, was found to be able to phosphorylate both ethanolamine
and choline, even though choline was the preferred substrate,
with a Km 80 times lower than that of ethanolamine. The Km
values for choline, ethanolamine and ATP were 31.4 +− 2.6 μM,
2.56 +− 0.31 mM and 20.6 +− 1.96 μM respectively. Further sub-
strate specificity analysis revealed that both TbEK1 and TbC/EK2
were able to tolerate various modifications at the amino group,
with the exception of a quaternary amine for TbEK1 (choline)
and a primary amine for TbC/EK2 (ethanolamine). Both enzymes
recognized analogues with substituents on C-2, but substitutions
on C-1 and elongations of the carbon chain were not well tolerated.
Key words: choline kinase, ethanolamine kinase, Kennedy
pathway, Trypanosoma brucei.
INTRODUCTION
The zwitterionic glycerophospholipids GPCho (glycerophos-
phocholine) and GPEtn (glycerophosphoethanolamine) are the
two most abundant phospholipid species in eukaryotic cells and
many bacteria [1]. In the parasitic protozoan Trypanosoma brucei,
the agent of African sleeping sickness, GPCho accounts for
approximately half of all phospholipids in both life-cycle stages,
whereas GPEtn forms between 16 and 21% [2]. These phos-
pholipids contribute an important structural role to the membrane
and, in addition, determine membrane fluidity and cell-surface
charge. Their biosynthesis and utilization is, not surprisingly,
implicated in a variety of cellular processes [1]. In mammals,
GPCho is an important source of signalling molecules, and the
biosynthetic intermediate PtdCho (phosphatidylcholine) has been
reported to be a mitogen required for DNA synthesis induced
by growth factors [3]. Owing to its physicochemical properties,
GPEtn has a tendency to form non-bilayer structures, and its
incorporation into membranes affects the processes of membrane
trafficking and the folding, stabilization and incorporation of
certain proteins into membranes [4]. Moreover, GPEtn is utilized
in the biosynthesis of GPI (glycosylphosphatidylinositol), a
complex glycolipid that anchors proteins to the exterior leaflet
of eukaryotic plasma membranes [5–7]. This is particularly
important for the bloodstream form of T. brucei, which expresses
a dense cell-surface coat (107 molecules per parasite) of a GPI-
anchored VSG (variant-surface glycoprotein). This coat prevents
attack by components of the innate immune system and, by
undergoing antigenic variation, allows the parasite to evade a
specific immune response by the host.
The biosynthesis of the GPI anchor has been genetically [8–10]
and chemically [11] validated as a drug target in the bloodstream
form of T. brucei. Thus disruption of the biosynthesis of GPEtn
could prevent the formation of mature GPI-anchored VSG and
lead to clearance of the parasite by the host’s immune system.
Owing to the major structural and functional roles of GPCho
and GPEtn in T. brucei, disruption of their biosynthetic pathways
is likely to interfere with the parasite biology in multiple ways
and thus the enzymes involved become of interest as possible
novel targets for chemotherapy. Indeed, it has been proposed
that the mode of action of lysophospholipid analogues (e.g.
miltefosine, edelfosine or ilmofosine) used currently against other
trypanosomatid parasites, i.e. Leishmania major, are involved in
the inhibition of GPCho biosynthesis [12].
GPEtn and GPCho are synthesized de novo via two branches
of the same metabolic pathway, the Kennedy pathway [13]
(Figure 1). Ethanolamine and choline are readily phosphorylated
to generate PtdEtn (phosphatidylethanolamine) and PtdCho,
which are subsequently activated to high-energy donors, CDP-
ethanolamine and CDP-choline respectively, before they are
coupled to diacylglycerol to form GPEtn and GPCho. For this
reason, the two branches of the Kennedy pathway are often
Abbreviations used: C/EK, choline/ethanolamine kinase; EK, ethanolamine kinase; GPCho, glycerophosphocholine; GPEtn, glycerophosphoethan-
olamine; GPI, glycosylphosphatidylinositol; GPSer, glycerophosphoserine; HPTLC, high-performance TLC; LB, Luria–Bertani; MALDI, matrix-assisted
laser-desorption ionization; ORF, open reading frame; PtdCho, phosphotidylcholine; PtdEtn, phosphatidylethanolamine; RT, reverse transcription; Tb,
Trypanosome brucei; TEV, tobacco etch virus; TOF, time-of-flight; UTR, untranslated region; VSG, variant-surface glycoprotein.
1 To whom correspondence should be addressed (email tks1@st-andrews.ac.uk).
The nucleotide sequence data reported for choline/ethanolamine kinase and ethanolamine kinase of Trypanosoma brucei have been submitted to the
DDBJ, EMBL, GenBank® and GSDB Nucleotide Sequence Databases under accession numbers AM939568 and AM939569 respectively.
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Figure 1 Pathways for the biosynthesis of the aminoglycerophospholipids
GPCho and GPEtn
The two branches of the Kennedy pathway are (a) the CDP-choline pathway and (b) the
CDP-ethanolamine pathway. The relevant steps are discussed in the text. CK, choline kinase
(Tb11.18.0017/Tb927.5.1140); CCT, CTP:phosphocholine cytidyltransferase (Tb10.389.0730);
CPT, diacylglycerol:CDP-choline cholinephosphotransferase (Tb10.6k15.1570); EK, ethanolam-
ine kinase (Tb11.18.0017/Tb927.5.1140); ECT, CTP:phosphoethanolamine cytidyltransferase
(Tb11.01.5730); EPT, diacylglycerol:CDP-ethanolamine ethanolaminephosphotransferase
(Tb10.6k15.1570); PSD, phosphatidylserine decarboxylase (Tb09.211.1610); PEMT,
phosphatidylethanolamine methyltransferases; DAG, diacylglycerol. The dashed box indicates
methyltransferase enzymes which are not present in either T. brucei or T. cruzi, but are present
in L. major.
referred to as the CDP-ethanolamine or CDP-choline pathways.
A second major pathway for the formation of GPEtn is via
GPSer (glycerophosphoserine) decarboxylation: GPSer, which is
formed through the action of a phosphatidylserine synthase, is
decarboxylated by a phosphatidylserine decarboxylase to form
GPEtn. In most eukaryotic cells, GPCho can also be generated
from GPEtn by three methylation steps. However, according to the
tritryp genomes (http://www.genedb.org), these methyltransferase
genes are not present in either T. brucei or Trypanosoma cruzi,
but interestingly are present in L. major; this has been confirmed
experimentally (T.K. Smith, unpublished work).
Although the presence of the Kennedy pathway was demon-
strated in T. brucei [14], the constituent enzymes have never been
characterized. In the present paper, we report investigations into
the first steps of both branches of the Kennedy pathway, involving
molecular cloning, recombinant expression, purification and
detailed kinetic characterization of both ethanolamine and choline
kinases (EK and CK respectively) from T. brucei.
EXPERIMENTAL
Organisms and reagents
T. brucei strain 427 was used as a source of genomic DNA.
Escherichia coli strains DH5α, XL-1 blue and TOP10 (Invitrogen)
competent cells were used for routine manipulation, and strain
BL21-Gold(DE3) (Novagen) for protein overexpression. All
chemicals were purchased from either Sigma–Aldrich or Fluka.
Restriction endonucleases and DNA-modifying enzymes were
from New England Biolabs or Promega. [2-3H]Ethanolamine
(50.0 Ci/mmol) and [methyl-3H]choline (82.0 Ci/mmol) were
purchased from GE Healthcare.
RNA isolation and cDNA synthesis
Total RNA was isolated from bloodstream-form T. brucei using
the RNeasy mini kit (Qiagen). A TbC/EK2 (T. brucei choline/
ethanolamine kinase 2)-specific cDNA was generated and ampli-
fied using a mini-exon-specific forward primer, 5′-CGCGGATC-
CGAACGCTATTATTAGAACAGTTTCTGTAC-3′, in combina-
tion with an ORF (open reading frame)-specific reverse primer, 5′-
CTTCTGTTCCACGGGTATAGTC -3′, specific for the sequence
of TbC/EK2 using the SuperScript III One step RT (reverse
transcription)–PCR kit with Platinum Taq (Invitrogen). The
amplified cDNAs were purified (QIAquick PCR purification kit,
Qiagen), ligated into pCR®-Blunt II TOPO® (Invitrogen) and
sequenced.
Cloning of the TbC/EK1 gene and construction of the
pET15b-TbC/EK1 expression vectors
Using the Saccharomyces cerevisiae EK gene sequence as
a query, two putative C/EK (choline/ethanolamine kinase)
genes were identified in the T. brucei genome database (http://
www.genedb.org) using tBlastN. The two putative ORFs
(Tb11.18.0017 for TbC/EK1, and Tb927.5.1140 for TbC/EK2)
together with ∼350 bp of their 5′- and 3′-UTRs (untranslated
regions), were amplified from T. brucei strain 427 genomic
DNA using Pfu DNA polymerase and the forward and
reverse primers 5′-ATAAGTAAGCGGCCGCCCGCCTAAG-
TTAGAAGTTGCGCT-3′ and 5′-ATAAGTAAGCGGCCGCTC-
CAATAGCTCCAGGGAAGGAAAGGGACG-3′ for TbC/EK1;
and 5′-ATAAGTAAGCGGCCGCAAGTGCGTTGTGCAGGT-
CGGCGACGGT-3′ and 5′-ATAAGTAAGCGGCCGCCGTTGG-
AAGGAGGAAAACGGCCGAGG-3′ for TbC/EK2. The
resulting 2.1 kb (TbC/EK1 and UTRs) and 3.7 kb (TbC/EK2
and UTRs) fragments were cloned into pCR®-Blunt-II TOPO®.
Clones were sequenced and compared with the annotated
GenBank® sequences. A BamHI restriction site, internal to
the TbC/EK1 ORF was silenced by site-directed mutagenesis
using the forward primer 5′-GTGTTGAGGGGGATAAGC-
GAATCCATCGCATGGTTCAGC-3′, the reverse primer 5′-GC-
TGAACCATGCGATGGATTCGCTTATCCCCCTCAACAC-3′
and the QuikChange® site-directed mutagenesis kit (Stratagene).
The TbC/EK1 ORF was PCR-amplified from the TOPO®
construct with Pfu polymerase using the forward and reverse
primers 5′-GGAATTCCATATGATGGAGGTGGCTGTGGG-
GCAC-3′ and 5′-CGCGGATCCGCGTTATGAAGATGCACTA-
AACTC-3′ respectively. The amplicon was purified (QIAquick
PCR purification kit; Qiagen), ligated into pCR®-Blunt II
TOPO® and sequenced. Using the NdeI and BamHI restriction
sites (underlined in primer sequences), the putative TbC/EK1
was ligated into the expression vector pET-15b (Novagen)
modified with a TEV (tobacco etch virus) protease cleavage site
(in place of a thrombin cleavage site) using the same restriction
sites generating the pET-15bTEV-TbC/EK1 construct. The same
procedure was employed to ligate the putative TbC/EK2 into
the same vector using the forward and reverse primers 5′-GG-
AATTCCATATGATGGCATTACGACCGTTCCCG-3′ and 5′-
CGCGGATCCGCGTCAGGAAAGAAGCCCCTTCTC-3′ res-
pectively.
The D287A and D267A mutants of TbC/EK1 were generated
using the QuikChange® site-directed mutagenesis kit with
the forward and reverse primers 5′-GGCGCACTGAAGAT-
TATTGcCTTCGAGTATGCAAAACG-3′ and 5′-CGTTTTGC-
ATACTCGAAGgCAATAATCTTCAGTGCGCC-3′ respectively
for the D287A mutant and the forward and reverse primers 5′-GA-
GTACGTGCCACAATGcCCTGCTCAGCGGC-3′ and 5′-GC-
CGCTGAGCAGGgCATTGTGGCACGTACTC-3′ respectively
for the D267A mutant (the lower case letters in the primers
highlight the mutated bases). All DNA sequencing was performed
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Figure 2 A Tcoffee alignment of the predicted amino acid sequences of TbEK1 (formerly TbC/EK1) and TbC/EK2 with CKs and EKs of other eukaryotic
organisms: T. cruzi (Swiss-Prot accession number Q4E3A9), L. major (Q4FYH6 and Q4FWX2) and Homo sapiens (Q9HBU6)
Residues are shaded according to percentage similarity using the Jalview 2.08.1 software. The boxes highlight the choline kinase motif and Brenner’s phosphotransferase motif. The two aspartate
residues marked by an asterisk were mutated in TbEK1 to generate the catalytically inactive mutants D267A and D286A.
by The Sequencing Service (College of Life Sciences, University
of Dundee; http://www.dnaseq.co.uk) using Applied Biosystems
Big-Dye version 3.1 chemistry on an Applied Biosystems model
3730 automated capillary DNA sequencer.
Expression and purification of TbC/EK1 and TbC/EK2
Overproduction and sample preparation
The pET-15bTEV-TbC/EK1 and the pET-15bTEV-TbC/EK2
constructs were transformed in BL21-Gold(DE3) cells and
clones selected on LB (Luria–Bertani) agar plates containing
carbenicillin (100 μg/ml). Single colonies were grown at 37 ◦C
in LB medium containing carbenicillin (50 μg/ml) until the
D600 was between 0.5 and 0.7, at which point recombinant
protein expression was induced with 1 mM IPTG (isopropyl β-D-
thiogalactoside) and grown for 16 h at room temperature (25 ◦C).
Cells were harvested by centrifugation at 3500 g for 20 min at 4 ◦C
before being suspended in buffer A (50 mM Tris/HCl, pH 8.0,
300 mM NaCl and 10 mM imidazole). Cells were lysed in the
presence of DNase I, either by sonication or using a French press,
and the lysate was cleared by centrifugation at 35000 g for 30 min
at 4 ◦C.
Purification and gel filtration
The cleared lysate was applied to a 1 ml HisTrapTM FF crude
column or a 5 ml HisTrapTM column (GE Healthcare) pre-loaded
with Ni2+. Unbound proteins were removed by washing the
column with 15 column vol. of buffer A, whereas TbC/EK1 and
TbC/EK2 were eluted with an imidazole gradient in the same
buffer.
Fractions containing TbC/EK1 or TbC/EK2 were pooled,
dialysed against 50 mM Tris/HCl (pH 8) and 300 mM NaCl
and purified further through a Superdex200 16/60 gel-filtration
column (GE Healthcare), run in the same buffer at a rate of
1 ml/min. Low and High Molecular Weight Calibration Kits
(GE Healthcare) were used to determine the molecular mass
and the oligomeric state of the proteins. Purity of protein
samples was assessed by SDS/PAGE (4–12 and 10% gels) and
MALDI (matrix-assisted laser-desorption ionization)–TOF (time-
of-flight)-MS (Proteomics Facility, College of Life Sciences,
University of Dundee).
Assay of TbC/EK activity
EK or CK activity was measured by a spectrophotometric coupled
assay as described previously [15]. The assay contained 50 mM
Mops (pH 7.8), 150 mM KCl, 6 mM MgCl2, 0.5 mg/ml BSA,
1 mM phosphoenolpyruvate, 0.5 mM NADH, 7 units/ml pyruvate
kinase, 32 units/ml lactate dehydrogenase and 2 μg/ml TbC/EK1
or 1 μg/ml TbC/EK2. Concentrations of ATP and ethanolamine
(or choline) were varied, and the rate of the reaction was monitored
by the decrease in absorbance at 340 nm (a consequence of
NADH oxidation) in a Shimadzu UV-1601 spectrophotometer.
The Enzyme Kinetics module of SigmaPlot (SPSS) was used to
analyse and fit the kinetic data.
The pH optimum was assessed by measuring TbC/EK1 and
TbC/EK2 activities at various pHs: sodium acetate (pH 5.0), Bis-
Tris/propane or Mops (pH 6.5), Tris/HCl (pH 7.0, 8.0 and 8.5),
Mops (pH 6.0, 7.0, 7.4 and 7.8) and glycine (pH 9.0). Various
ethanolamine and choline analogues were tested as substrates at
least in triplicate on 96-well plates using a SpectraMAX 340PC
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Figure 3 Expression and purification of recombinant TbEK1 (formerly TbC/EK1) and TbC/EK2 in E. coli
(A) TbEK1 protein samples from each purification step were separated by SDS/PAGE (4–12 % gel) and stained with Coomassie Brilliant Blue. Lane 1, total E. coli cellular protein after induction;
lane 2, cleared cell lysate; lane 3, Ni2+ column wash at 20 mM imidazole; lane 4, Ni2+ column wash at 50 mM imidazole; lanes 5–8, subsequent elutions from the Ni2+ column at 250 mM imidazole.
MW, molecular mass (in kDa). (B) TbC/EK2 protein samples from each purification step were separated by SDS/PAGE (10 % gel) and stained with Coomassie Brilliant Blue. Lane 1, cleared E. coli
cell lysate; lanes 2–4, washes; lanes 5–8, peak of TbC/EK2 elution at 220 mM imidazole. MW, molecular mass (in kDa). (C) Protein samples after gel filtration separated by SDS/PAGE. Lane 1,
TbEK1 (4–12 % gel); lane 2, TbC/EK2 (10 % gel). MW, molecular mass (in kDa). (D) Determination of native molecular masses of TbEK1 and TbC/EK2. The elution from the gel-filtration column
indicates that both TbEK1 (black arrow) and TbC/EK2 (white arrow) are present as dimers. The following proteins were used as standards: (a) ferritin (440 kDa), (b) conalbumin (75 kDa), (c) carbonic
anhydrase (29 kDa), and (d) RNase A (13.7 kDa).
plate reader (Molecular Devices), and those deemed as non-
substrates were tested as inhibitors by pre-incubation at 1 mM for
5 min before the addition of ethanolamine or choline (0.1 mM).
Direct EK and CK activity assays were performed by assessing
the production of PtdEtn or PtdCho, using a modified method of
Kim et al. [16]. Briefly, 2 μg of purified protein was incubated
with a reaction mixture (total volume of 50 μl) of 100 mM
Mops (pH 7.8), 6 mM MgCl2 and 5 mM ATP, with either
2 mM ethanolamine and 0.2 μCi of [3H]ethanolamine or 2 mM
choline and 0.2 μCi of [3H]choline at 37 ◦C for 20 min and
quenched by boiling at 100 ◦C for 5 min. Substrates and products
were separated by HPTLC (high-performance TLC) using silica
60 plates with methanol/0.6% NaCl/ammonium hydroxide
(10:10:1, by vol.) as solvent. Radiolabelled species were detected
by fluorography at −70 ◦C after spraying with En3Hance and
using Kodak XAR-5 film with an intensifying screen. Unlabelled
ethanolamine and PtdEtn standards were run in parallel and
visualized by spraying with ninhydrin (0.2% in water-saturated
butan-1-ol). Unlabelled PtdCho was run in parallel and visualized
by iodine staining.
RESULTS AND DISCUSSION
Genomic identification and cloning of TbC/EK1 and TbC/EK2
Two putative C/EKs were identified in the T. brucei genome
database (http://www.genedb.org); these putative ORFs were
PCR-amplified from genomic DNA, cloned and sequenced. Two
potential initiating methionine residues were detected in the
TbC/EK2 ORF; this ambiguity was resolved by amplification
and sequencing of the first ∼350 bp of the RT–PCR product
using total RNA, a forward primer against the mini-exon and a
reverse primer specific for the TbC/EK2 ORF. From the cDNA
sequence (Supplementary Figure S1 at http://www.BiochemJ.org/
bj/415/bj4150135add.htm), the second methionine residue was
identified as being the initiating residue. Interestingly, there seems
to be an extra ‘stuffer’ sequence (65 bp) between this and the mini-
exon (Supplementary Figure S1), which may represent some form
of regulatory element, a concept we are currently investigating.
The predicted molecular masses of the deduced amino acid
sequences are 49.1 kDa (431 amino acids) for TbC/EK1 and
70.1 kDa (628 amino acids) for TbC/EK2. An alignment of the
translated sequences of TbC/EK1 and TbC/EK2 with previously
characterized or putative C/EKs from other organisms (Figure 2)
shows significant similarities. Even though the N-terminal region
is not generally well conserved among C/EKs, the C-terminal
portion contains two highly conserved regions. Brenner’s motif
(Figure 2) has been identified in many enzymes catalysing
phosphotransfer reactions, such as protein kinases and atypical
kinases (the superfamily that includes the C/EK family) [17].
The second conserved cluster (Figure 2) is found specifically
in members of the C/EK family and is referred to as the choline
kinase motif. Previous site-directed mutagenesis studies and struc-
tural studies in Caenorhabditis elegans CKα2 [18,19] and the
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Figure 4 Analysis of PtdEtn formation by TbEK1 (formerly TbC/EK1)
(A) Reaction catalysed by TbEK1. EtN, ethanolamine. (B) The substrate ethanolamine (EtN) and the product PtdEtn of the reaction were separated by HPTLC, as described in the Experimental section.
Lanes 1–6, autoradiography detection. Lane 1, [3H]ethanolamine standard; lane 3, standard reaction with TbEK1; lanes 2 and 4, no enzyme or no Mg2+ added to the reaction mixture respectively
(negative controls); lanes 5 and 6, standard reaction with TbEK1 mutants D267A and D286A respectively; lane 7, ethanolamine standard; lane 8, PtdEtn standard detected by ninhydrin. (C) Enzymatic
activities of wild-type (WT) TbEK1 and mutants D267A and D286A assessed by spectrophotometric coupled assay as described in the Experimental section. Results are means +− S.D. (n 3). The
inset shows an SDS/PAGE gel of the purified proteins (wild-type and mutants). MW, molecular mass (in kDa).
Table 1 Kinetic values for recombinantly expressed and purified TbEK1 (formerly TbC/EK1) and TbC/EK2
Results are means +− S.D. (n 3).
V max K m K m K m k cat k cat/K m k cat/K m k cat/K m
Enzyme (μmol/min per mg of protein) choline (μM) ethanolamine (μM) ATP (μM) (s−1) choline (s−1 · mM−1) ethanolamine (s−1 · mM−1) ATP (s−1 · mM−1)
TbEK1 7.62 +− 0.07 0.0 +− 0.0 18.4 +− 0.9 219.2 +− 29 6.56 – 356.53 29.93
TbC/EK2 10.67 +− 0.18 31.4 +− 2.6 2560 +− 310 20.6 +− 1.96 12.91 411.25 5.04 626.86
Table 2 Substrate specificity of TbEK1 (formerly TbC/EK1) and TbC/EK2 to utilize analogues modified at the amino group of the acceptor substrate
Results are means +− S.D. (n 3).
R1 R2 R3 Compound TbEK1 relative rate∗ TbC/EK2 relative rate†
-CH3 -CH3 -CH3 Choline 0.03 +− 1.59 100.00 +− 7.97
-H -H -H Ethanolamine 100.00 +− 1.65 33.34 +− 3.34
-H -H -CH3 N-Methylethanolamine 106.58 +− 9.18 135.90 +− 3.64
-H -CH3 -CH3 N,N-Dimethylethanolamine 76.54 +− 4.86 153.33 +− 2.77
-H -H -CH2CH3 N-Ethylethanolamine 97.38 +− 1.59 150.57 +− 8.40
-H -CH2CH3 -CH2CH3 N,N-Diethylethanolamine 47.75 +− 3.98 155.92 +− 4.32
-H -H -CH2CH2OH Diethanolamine 88.26 +− 0.78 138.86 +− 6.30
∗Analogues are compared with ethanolamine at the constant concentration of 1 mM and a saturating concentration of ATP to give a relative rate (ethanolamine = 100).
†Analogues are compared with choline at the constant concentration of 1 mM and a saturating concentration of ATP to give a relative rate (choline = 100).
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analysis of the crystal structures of human CKα [20] have
highlighted the importance of several of the amino acids in
substrate binding. Of particular importance are the two aspartate
residues marked by an asterisk in the alignment (Figure 2). These
residues are involved in the binding of ATP and the stabilization
of the transition state of the reaction, and their mutation leads to
complete enzyme inactivation [18,20].
Not surprisingly, TbC/EK1 and TbC/EK2 are most closely
related to C/EKs from other kinetoplastids. In the region of the
alignment shown in Figure 2, TbC/EK1 is 63% identical with
a putative C/EK from T. cruzi and TbC/EK2 is 40% identical
with a putative C/EK from L. major. The similarity towards
previously characterized C/EKs from human, yeast, C. elegans
and Plasmodium falciparum is much lower (results not shown),
with the exception of Brenner’s and the choline kinase motifs.
Recombinant expression and purification of TbC/EK1 and TbC/EK2
In order to confirm that the putative TbE/CK1 and TbE/CK2 are
catalytically active, the two ORFs were cloned into the vector
pET-15bTEV. This vector encodes an N-terminal hexahistidine
epitope tag followed by a TEV protease site, which allowed
purification of the recombinant proteins via Ni2+ ion-affinity
chromatography (Figures 3A and 3B). MALDI–TOF-MS of the
recombinant TbC/EK1 and TbC/EK2 were very close to their
theoretical masses of 51655 and 72614 Da respectively. The
proteins TbC/EK1 and TbC/EK2 were purified further by gel
filtration (Figure 3C). Elution from the gel-filtration column
showed that both TbC/EK1 (black arrow) and TbC/EK2 (white
arrow) exhibited a dimeric state in solution (Figure 3D). This
is similar to most of the C/EKs from other sources [21–23],
with the notable exception of the monomeric P. falciparum CK
[15]. Typical yields were 10 and 15 mg/l of bacterial culture for
TbC/EK1 and TbC/EK2 respectively. TbC/EK1 was found to lose
activity over time, being lost completely after a couple of days. It
is also prone to precipitation upon freeze–thawing, and therefore
assays were preformed on freshly prepared batches. TbC/EK2,
on the other hand, was stable, and freeze–thawing did not lead to
loss of activity or precipitation.
Kinetic analysis of TbC/EK1 and TbC/EK2
Previously characterized C/EKs from various sources [15,21–25]
have exhibited different specificity towards the two substrates,
choline and ethanolamine. It was therefore necessary to test the
activity of the purified proteins in order to ascertain whether they
were able to catalyse the phosphorylation of both choline and
ethanolamine or if they showed selectivity to each branch of the
Kennedy pathway.
TbC/EK1 was found to be able to catalyse the formation
of PtdEtn from ethanolamine, in an ATP- and Mg2+-dependent
manner (Figures 4A and 4B). However, the enzyme was unable
to catalyse the formation of PtdCho from choline, in the presence
of ATP and magnesium (Tables 1 and 2). This restricts the
specificity of this kinase to the CDP-ethanolamine branch of the
Kennedy pathway and, for this reason, TbC/EK1 was renamed
TbEK1. To our knowledge, this is the first ethanolamine-specific
kinase to be recombinantly expressed, purified to homogeneity
and extensively characterized.
Kinetic analysis showed that TbEK1 displayed a pH optimum at
pH 8.0 (Figure 5A), with a Km of 18.4 +− 0.9 μM for ethanolamine(Figure 5B) and a Km of 219 +− 29 μM for ATP (Figure 5C),
which is in reasonable agreement with a previously reported
Km value of 2.75 μM for EK activity from crude trypanosome
homogenates [14]. The Vmax of TbEK1 is 7.62 +− 0.07 μmol/min
per mg of protein, corresponding to a kcat of 6.56 s−1 (Table 1).
Figure 5 Kinetic analysis of TbEK1 (formerly TbC/EK1)
(A) EK activity was measured spectrophotometrically as a function of pH as described in the
Experimental section. Results are means +− S.D. of three measurements. (B, C) Determination
of TbEK1 Michaelis–Menten constants for ethanolamine and ATP (insets are Lineweaver–Burk
plots). (B) ATP concentration was held constant (5 mM), while ethanolamine concentration was
varied. (C) Ethanolamine concentration was held constant (2 mM), while ATP concentration
was varied.
This turnover rate/specific activity compares favourably with the
previously reported activities of 346 nmol/min per mg of protein
for the yeast EK [16] and 10.73 μmol/min per mg of protein for a
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Figure 6 Analysis of PtdCho formation by TbC/EK2
(A) Reaction catalysed by TbC/EK2. Cho, choline. (B) The substrate ethanolamine (EtN) and the product PtdEtn of the reaction were separated by HPTLC as described in the Experimental section.
Lanes 1–7, ninhydrin detection. Lane 1, ethanolamine standard; lane 2, PtdEtn standard; lane 3, standard reaction with TbC/EK2; lanes 4–6, no Mg2+ , no ethanolamine or no ATP added to the
reaction mixture respectively (negative controls). (C) The substrate choline (Cho) and the product PtdCho of the reaction were separated by HPTLC as described in the Experimental section.
Lanes 1–6, autoradiography detection; lane 7, detection by iodine staining. Lane 1, [3H]choline standard; lane 2, standard reaction with TbC/EK2; lanes 3–6, no enzyme, no Mg2+ , no [3H]-choline
or no ATP added to the reaction mixture respectively (negative controls); lane 7, PtdCho standard visualized by iodine staining.
soya bean EK [25]. Two catalytically inactive mutants of TbEK1
were generated by substitution of alanine for Asp267 and Asp286
(Figures 4B and 4C), thus confirming the crucial importance of
these two residues in the catalytic mechanism of this kinase.
TbC/EK2, on the other hand, was found to be able to
phosphorylate both ethanolamine (Figure 6B) and choline
(Figures 6A and 6C), even though choline was the preferred
substrate (Tables 1 and 2), with a Km 80 times lower than that
of ethanolamine. TbC/EK2 was also dependent upon ATP and
Mg2+ for activity (Figures 6B and 6C) with a pH optimum of 7.8
(Figure 7A). Kinetic analysis showed that TbC/EK2 displayed
Km values for choline, ethanolamine and ATP of 31.4 +− 2.6 μM,
2.56 +− 0.31 mM and 20.6 +− 1.96 μM respectively with a Vmax of
10.67 +− 0.18 μmol/min per mg of protein and a kcat of 12.91 s−1(Figures 7B–7D and Table 1). This value is in the range of
activities reported for other eukaryotic C/EKs, and more than
ten times higher than the CK from P. falciparum [15].
Since the TbC/EK2 Km value for ethanolamine is several orders
of magnitude higher than that of TbEK1 and the fact that levels
of ethanolamine in human plasma are in the micromolar range
[26], one can reasonably assume that TbEK1 accounts for the
vast majority of the ethanolamine-phosphate formation in the try-
panosome. There were no differences in the kinetics between
the hexahistidine-tagged and untagged (TEV-cleaved) versions of
either TbEK1 or TbC/EK2, thus the tagged versions were used as
this decreases preparation time and increases stability, which is
especially important for TbEK1.
Acceptor specificity of TbEK1 and TbC/EK2
The ability of the two enzymes to utilize chemically modified
substrates for the phosphotransfer reaction was investigated
using a variety of ethanolamine and choline analogues, with
modifications either at the amino or the hydroxy moieties, or
with additional substituents on the two-carbon backbone. Each
analogue was compared with ethanolamine (for TbEK1) or
choline (for TbC/EK2) at a constant substrate concentration
(1 mM) and a fixed saturating concentration of ATP to give a
relative rate (ethanolamine/choline = 100) (Tables 2–4).
TbEK1 was able to tolerate various modifications at the amino
group, including secondary and tertiary amino modifications,
despite having been shown earlier not to process choline
(Table 2). As shown in Table 3, single methyl and ethyl
substituents on the carbon backbone at C-2 [R(−)2-aminobutan-1-
ol, S(+)2-aminobutan-1-ol, R(−)2-aminopropan-1-ol and S(+)2-
aminopropan-1-ol] are well tolerated, but the introduction of
a second methyl group at C-2 (2-amino-2-methylpropan-1-ol)
or a negatively charged carboxy group (L-serine) resulted in
greatly reduced or non-detectable activity respectively. Methyl
substitutions on C-1 (R(−)1-aminopropan-2-ol and S(+)1-
aminopropan-2-ol) diminished the ability of the compound to act
as a substrate, but to varying degrees in a stereospecific fashion.
The increase of the carbon backbone length by one methylene unit
(3-aminopropan-1-ol) led to a pronounced decrease in activity,
whereas the increase by an ethylene unit (4-aminobutan-1-ol),
eliminated substrate activity completely.
TbC/EK2 was able to accept analogues modified at the amino
group as substrates of the reaction; in fact, secondary and
tertiary amino modifications were better than choline. Notably,
of the compounds tested, ethanolamine was the poorest acceptor
substrate (Table 2); these findings are in contrast with those
with CK from S. cerevisiae [24], where N-methylethanolamine
and N,N-dimethylethanolamine were as poor substrates as
ethanolamine. Compounds with methyl and ethyl alterations on
C-2 are good substrates only in the (S) configuration; R(−)2-
aminobutan-1-ol and R(−)2-aminopropan-1-ol are much poorer
substrates, as well as 2-amino-2-methylpropan-1-ol, which bears
two methyl groups at C-2 (Table 3). A reduction of activity is seen
with the elongation of the carbon chain, but it is not abolished
even when increased by an ethylene unit (4-aminobutan-1-ol).
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Figure 7 Kinetic analysis of TbC/EK2
(A) CK activity was measured spectrophotometrically as a function of pH as described in the Experimental section. Results are means +− S.D. of three measurements. (B–D) Determination of
TbC/EK2 Michaelis–Menten constants for choline, ethanolamine and ATP (insets are Lineweaver–Burk plots). ATP concentration was held constant (5 mM), while choline (B) or ethanolamine (EtN)
(C) concentrations were varied. (D) Choline concentration was held constant (2 mM), while ATP concentration was varied.
The introduction of a negative charge (L-serine), as well as the
introduction of substituents at C-1 [R(−)1-aminopropan-2-ol and
S(+)1-aminopropan-2-ol] are not tolerated (Table 3). That the
enzyme is relatively more tolerant of substituents on C-2 is in
agreement with the previous studies on the yeast orthologue [24].
As expected, modifications at the hydroxy group (Table 4) resulted
in no detectable reactivity for either TbEK1 or TbC/EK2.
Analogues deemed as non-substrates were tested as potential
inhibitors by pre-incubation at 1 mM for 5 min before the
addition of ethanolamine or choline (0.1 mM) to TbEK1 and
TbC/EK2 respectively. However, none of the potential inhibitory
analogues showed any inhibitory effect (<5%) on either TbEK1
or TbC/EK2 activity.
Previous studies in T. brucei [14] demonstrated that ethanola-
mine analogues, such as N-methylethanolamine, N-ethyle-
thanolamine, N,N-dimethylethanolamine, S(+)-2-aminobutan-
1-ol or R(−)-2-aminobutan-1-ol, can be recognized by the
ethanolamine transport system, whereas choline is not. There
was ambiguity as to whether these compounds were acting
as inhibitors of the transporter or merely competing with
ethanolamine to be transported into the cell. If the latter case were
true, our results suggest these analogues could be phosphorylated
by TbEK1 and/or TbC/EK2, and possibly proceed further in the
Kennedy pathway, leading to the formation of unusual PtdEtn
analogues, a concept we are currently pursuing.
Conclusions
African sleeping sickness is a neglected disease, which
urgently requires new drug therapies. Characterizing fundamental
differences in the biochemical pathways and enzymes therein of
the parasite and its mammalian host, is an important first step
towards this goal. Thus the present study represents the first
identification and detailed molecular characterization of the two
putative C/EKs in T. brucei. TbEK1 is committed to only the CDP-
ethanolamine branch of the Kennedy pathway since it is unable
to phosphorylate choline; TbC/EK2, on the other hand, was able to
phosphorylate choline much more efficiently than ethanolamine.
The substrate specificities for each kinase were determined,
providing crucial information on the structural requirements for
ligand recognition.
Analysis of the roles of TbEK1 and TbC/EK2 in parasite
survival will be crucial to investigate their potential as drug targets
for the development of new chemotherapeutic agents against
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Table 3 Substrate specificity of TbEK1 (formerly TbC/EK1) and TbC/EK2 to utilize analogues modified by extra substitutents on the carbon backbone of the
acceptor substrate
Results are means +− S.D. (n 3).
R1 R2 R3 Compound TbEK1 relative rate∗ TbC/EK2 relative rate†
-N+(CH3) 3 -H -H Choline 0.03 +− 1.59 100.00 +− 7.97
-NH2 -H -H Ethanolamine 100.00 +− 1.65 33.34 +− 3.34
-NH2 -CH3 -H R(−)-2-Aminopropan-1-ol 107.91 +− 2.77 109.94 +− 15.42
-NH2 -CH3 -H S(+)-2-Aminopropan-1-ol 93.75 +− 4.02 22.38 +− 1.87
-NH2 -(CH3)2 -H 2-Amino-2-methylpropan-1-ol 25.58 +− 3.98 46.41 +− 6.57
-NH2 -CH2CH3 -H S(+)-2-Aminobutan-1-ol 114.07 +− 5.84 40.72 +− 4.93
-NH2 -CH2CH3 -H R(−)-2-Aminobutan-1-ol 101.74 +− 5.76 130.40 +− 9.10
-NH2 -COOH -H L-Serine 0.94 +− 2.25 0.00 +− 0.00
-NH2 -H -CH3 R(−)-1-Aminopropan-2-ol 52.41 +− 4.50 7.16 +− 0.60
-NH2 -H -CH3 S(+)-1-Aminopropan-2-ol 6.07 +− 2.13 1.37 +− 0.15
-CH2NH2 -H -H 3-Aminopropan-1-ol 37.52 +− 2.96 44.52 +− 4.33
(CH2)2NH2 -H -H 4-Aminobutan-1-ol 0.05 +− 1.93 59.95 +− 6.00
∗Analogues are compared with ethanolamine at the constant concentration of 1 mM and a saturating concentration of ATP to give a relative rate (ethanolamine = 100).
†Analogues are compared with choline at the constant concentration of 1 mM and a saturating concentration of ATP to give a relative rate (choline = 100).
Table 4 Substrate specificity of TbEK1 (formerly TbC/EK1) and TbC/EK2 to
utilize analogues modified at the hydroxy group of the acceptor substrate
Results are means +− S.D. (n 3).
R Compound TbEK1 relative rate∗ TbC/EK2 relative rate†
-OH Choline 0.03 +− 1.59 100.00 +− 7.97
-OH Ethanolamine 100.00 +− 4.84 33.34 +− 3.34
-SH 2-Aminoethanethiol 0.01 +− 0.51 0.96 +− 0.30
-(OCH3)2 Aminoacetaldehyde dimethyl acetal 0.73 +− 0.63 0.57 +− 0.12
-SO3H Taurine 0.00 +− 0.13 0.02 +− 0.00
-H Ethylamine 0.01 +− 0.26 0.00 +− 0.00
-OSO3H 2-Aminoethyl hydrogen sulfate 0.54 +− 2.31 0.00 +− 0.00
-OOH Glycine 0.35 +− 0.72 0.85 +− 0.11
-OPO3H2 Phosphoethanolamine 0.25 +− 3.32 1.35 +− 0.29
-OCH3 2-Methoxyethylamine 0.00 +− 0.02 1.49 +− 0.28
-PO3H2 2-Aminoethyl phosphonic acid 0.08 +− 0.66 0.80 +− 0.18
∗Analogues are compared with ethanolamine at the constant concentration of 1 mM and a
saturating concentration of ATP to give a relative rate (ethanolamine = 100).
†Analogues are compared with choline at the constant concentration of 1 mM and a saturating
concentration of ATP to give a relative rate (choline = 100).
African sleeping sickness and perhaps other protozoan parasites.
The similarities in ligand recognition displayed by TbEK1 and
TbC/EK2 may guide the design of inhibitors able to target both
enzymes at once. Further work will characterize and assess the
importance of all steps of the two branches of the Kennedy
pathway, as well as their functional role(s) in the biology of the
trypanosome.
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Figure S1 Sequence of cDNA of TbC/EK2
Highlighted are the mini-exon sequence (grey box), the stuffer sequence (lower case) and the TbC/EK2 sequence (upper case). Double-underlined is the sequence of the internal reverse primer used
to generate TbC/EK2 cDNA; the sequence downstream of this point is inferred from the genomic sequence.
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